Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261411 | 1.00 | MAPT (0.39) | MAPTALDH1A1TP53TDP1ADORA2A | |
| SCHEMBL5263727 | 0.92 | MAPT (0.41) | MAPTALDH1A1TP53TDP1ADORA2A | |
| SCHEMBL5263723 | 0.92 | MAPT (0.41) | MAPTALDH1A1TP53TDP1ADORA2A | |
| SCHEMBL5260890 | 0.85 | KDM4E (0.38) | ALDH1A1FGFR4HSD11B1KMT2A | |
| SCHEMBL5260885 | 0.85 | KDM4E (0.38) | ALDH1A1FGFR4HSD11B1KMT2A | |
| SCHEMBL5260079 | 0.85 | ADORA2A (0.37) | ADORA2AFGFR4KMT2A | |
| SCHEMBL5260077 | 0.85 | ADORA2A (0.37) | ADORA2AFGFR4KMT2A | |
| SCHEMBL5258654 | 0.84 | ADORA2A (0.41) | MAPTALDH1A1ADORA2A | |
| SCHEMBL5258651 | 0.84 | ADORA2A (0.41) | MAPTALDH1A1ADORA2A | |
| SCHEMBL5259266 | 0.83 | NPC1 (0.47) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | claimed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | claimed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | claimed |
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | disclosed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | disclosed |
| US-6486322-B1 | Azaindole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2002-11-26 | — | — | US | disclosed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | FFAR4, AZI2, CNKSR1 | MAPT 4795/4885ALDH1A1 2745/4885TP53 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.